Author(s):
Leite, Ana Luísa ; Galo, Elisa ; Antunes, Ana ; Robalo, Brígida ; Amaral, Daniela ; Espada, Filipa ; Castro, Sofia ; Simões Dias, Sara ; Limbert, Catarina
Date: 2022
Persistent ID: http://hdl.handle.net/10362/136400
Origin: Repositório Institucional da UNL
Subject(s): body mass index (BMI); central precocious puberty (CPP); GnRH agonists; obesity; weight gain (WG); Pediatrics, Perinatology, and Child Health; SDG 3 - Good Health and Well-being; body mass index (BMI); body mass index (BMI); central precocious puberty (CPP); central precocious puberty (CPP); GnRH agonists; GnRH agonists; obesity; obesity; weight gain (WG); weight gain (WG); Pediatrics, Perinatology, and Child Health; Pediatrics, Perinatology, and Child Health; SDG 3 - Good Health and Well-being; SDG 3 - Good Health and Well-being
Description
Funding Information: We would like to thank all the colleagues who collected data for the National Database: Joana Serra, Unidade de Endocrinologia Pediátrica, Hospital Pediátrico de Coimbra, Portugal; Marcelo Fonseca, Unidade de Endocrinologia Pediátrica, Hospital Pedro Hispano, Matosinhos, Portugal; Maria João Oliveira, Unidade de Endocrinologia Pediátrica, Centro Materno Infantil do Norte, Porto, Portugal; Maria Miguel Gomes, Unidade de Endocrinologia Pediátrica, Hospital de Braga, Portugal; Paula Vieira, Serviço de Pediatria, Hospital São Francisco Xavier, Lisbon, Portugal; Rita Silva, Unidade de Endocrinologia Pediátrica, Hospital de São João, Porto, Portugal; Sónia Gomes, Unidade de Endocrinologia Pediátrica, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal; Susana Figueiredo, Serviço de Pediatria, Hospital de Viana de Castelo, Portugal; and Susana Pacheco, Unidade de Endocrinologia Pediátrica, Hospital Fernando da Fonseca, Amadora, Portugal. We also thank all children, adolescents, and their parents for their cooperation and understanding. This investigator-initiated study was supported by an unconditional research grant from Ipsen. Funding Information: We would like to thank all the colleagues who collected data for the National Database: Joana Serra, Unidade de Endocrinologia Pedi?trica, Hospital Pedi?trico de Coimbra, Portugal; Marcelo Fonseca, Unidade de Endocrinologia Pedi?trica, Hospital Pedro Hispano, Matosinhos, Portugal; Maria Jo?o Oliveira, Unidade de Endocrinologia Pedi?trica, Centro Materno Infantil do Norte, Porto, Portugal; Maria Miguel Gomes, Unidade de Endocrinologia Pedi?trica, Hospital de Braga, Portugal; Paula Vieira, Servi?o de Pediatria, Hospital S?o Francisco Xavier, Lisbon, Portugal; Rita Silva, Unidade de Endocrinologia Pedi?trica, Hospital de S?o Jo?o, Porto, Portugal; S?nia Gomes, Unidade de Endocrinologia Pedi?trica, Centro Hospitalar Universit?rio de Lisboa Central, Lisbon, Portugal; Susana Figueiredo, Servi?o de Pediatria, Hospital de Viana de Castelo, Portugal; and Susana Pacheco, Unidade de Endocrinologia Pedi?trica, Hospital Fernando da Fonseca, Amadora, Portugal. We also thank all children, adolescents, and their parents for their cooperation and understanding. This investigator-initiated study was supported by an unconditional research grant from Ipsen. Publisher Copyright: Copyright © 2022 Leite, Galo, Antunes, Robalo, Amaral, Espada, Castro, Simões Dias and Limbert.
Introduction: There are several concerns associated with gonadotropin-releasing hormone agonist (GnRHa) treatment for central precocious puberty (CPP), such as obesity and changes in body mass index (BMI). We aimed to investigate whether any anthropometric differences exist and if they persist over time. Methods: We conducted an observational study of Portuguese children (both sexes) diagnosed with CPP between January 2000 and December 2017, using a digital platform, in order to analyze the influence of GnRHa treatment on BMI-SD score (BMI-SDS). Results: Of the 241 patients diagnosed with CPP, we assessed 92 patients (8% boys) in this study. At baseline, 39% of the patients were overweight. BMI-SDS increased with treatment for girls but then diminished 1 year after stopping GnRHa therapy (p = 0.018). BMI-SDS variation at the end of treatment was negatively correlated with BMI-SDS at baseline (p < 0.001). Boys grew taller and faster during treatment than did girls (p < 0.001), and therefore, their BMI-SDS trajectory might be different. Conclusions: This study showed an increase of body weight gain during GnRHa treatment only in girls, which reversed just 1 year after stopping treatment. The overall gain in BMI-SDS with treatment is associated with baseline BMI-SDS.
